Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

23.44 -0.40 (-1.68%)
Streaming Delayed Price Updated: 12:58 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 640,549
Open 23.70
Bid (Size) 23.43 (100)
Ask (Size) 23.45 (400)
Prev. Close 23.84
Today's Range 23.39 - 23.84
52wk Range 16.57 - 31.77
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth Momentum ↗
Via Chartmill

Performance

YTD
-19.2%
-19.2%
1 Month
-9.6%
-9.6%
3 Month
+0.9%
+0.9%
6 Month
-2.1%
-2.1%
1 Year
+30.7%
+30.7%

More News

Read More
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals ↗
Via Chartmill
News headline image
Arcutis (ARQT) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Jumps on Q2 Beat and Raised Guidance ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup ↗
Via Chartmill
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% ↗
Via The Motley Fool
News headline image
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcutis Biotherapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Expands Board of Directors with Appointment of Chris Peetz
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide ↗
Via Chartmill
News headline image
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status ↗
Via MarketBeat
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis (ARQT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool

Frequently Asked Questions

Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?
Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.
What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?
Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?
The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market
What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?
The current price of Arcutis Biotherapeutics, Inc. - Common stock is 23.44
When was Arcutis Biotherapeutics, Inc. - Common stock last traded?
The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 09/10/26 12:58 PM ET
What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?
The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.18B
How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?
Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.